SCHEMBL21856545

SCHEMBL21856545

CC(C)Oc1cc(Cl)nc2ncccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 1/20 0.41
MEN1 O00255 1/20 0.39
POLB P06746 1/20 0.39
KMT2A Q03164 1/20 0.39
IGF1R P08069 1/20 0.39
G6PD P11413 1/20 0.38
SYK P43405 6/20 0.36
IDO1 P14902 1/20 0.36
CDC7 O00311 1/20 0.35
ROCK2 O75116 1/20 0.35
MAP4K4 O95819 1/20 0.35
PIM1 P11309 1/20 0.35
PRKACA P17612 1/20 0.35
CDK2 P24941 1/20 0.35
GSK3B P49841 1/20 0.35
HIPK2 Q9H2X6 1/20 0.35
CLK4 Q9HAZ1 1/20 0.35
IRAK4 Q9NWZ3 1/20 0.35
CCR1 P32246 1/20 0.35
CCR8 P51685 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8212392 0.83 G6PD (0.48) POLBIGF1RG6PDSYKIDO1
SCHEMBL1577560 0.80 LMNA (0.46) MEN1KMT2AIGF1RIDO1CDC7
SCHEMBL7497955 0.78 KMO (0.36) GRM5MEN1POLBKMT2ACDK2
SCHEMBL1577423 0.74 CCR1 (0.49) IGF1RIDO1CDC7ROCK2MAP4K4
SCHEMBL26676121 0.74 LTA4H (0.48) GRM5POLBL3MBTL1MAPT
SCHEMBL247512 0.73 L3MBTL1 (0.52) MEN1KMT2AIDO1CDC7ROCK2
SCHEMBL31444788 0.70 MEN1 (0.43) MEN1KMT2AIDO1CDC7ROCK2
SCHEMBL12426313 0.70 KDM4E (0.44) MEN1KMT2AIDO1CDC7ROCK2
SCHEMBL3513772 0.70 MEN1 (0.46) GRM5MEN1POLBKMT2AIRAK4
SCHEMBL30454073 0.70 MEN1 (0.46) GRM5MEN1POLBKMT2AIRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528803-B2 Inhibitors of αvβ6 integrin MORPHIC THERAPEUTIC, INC. (US) 2026-01-20 US disclosed
EP-3844162-B1 INHIBITORS OF ALPHA V BETA6 INTEGRIN MORPHIC THERAPEUTIC INC (US) 2025-01-01 EP disclosed
WO-2023192989-A2 PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS AZKARRA THERAPEUTICS, INC. (US) 2023-10-05 WO disclosed
US-20230242524-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC, INC. 2023-08-03 US disclosed
US-20230242524-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC, INC. 2023-08-03 US disclosed
US-20230242524-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC, INC. 2023-08-03 US disclosed
EP-3844162-A1 INHIBITORS OF av beta6 INTEGRIN Morphic Therapeutic, Inc. (US) 2021-07-07 EP disclosed
WO-2020081154-A1 INHIBITORS OF ανβ6 INTEGRIN MORPHIC THERAPEUTIC, INC. (US) 2020-04-23 WO disclosed
WO-2020081154-A1 INHIBITORS OF ανβ6 INTEGRIN MORPHIC THERAPEUTIC, INC. (US) 2020-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242524-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN ITGB6, ITGA6, ITGAV GRM5 2554/4885MEN1 3154/4885POLB 2459/4885
US-12528803-B2 Inhibitors of αvβ6 integrin ITGB2, ITGB6, ITGA2 GRM5 4145/4885MEN1 2751/4885POLB 4143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.